Amgen Recalls 944,142 Corlanor and Sensipar Bottles Over Foreign Matter

Q: Amgen recalled a million drug bottles for 'foreign matter.' What was it, and how did it bypass quality control?

The “foreign matter” has not been publicly identified beyond Amgen’s and the FDA’s description: it was an unexpected substance found on the outside of some tablets, localized to the tablet coating rather than inside the drug itself. Regulators said the material did not pose a meaningful clinical risk, and the recall was classified as Class II, meaning serious harm is considered unlikely. As for how it got through quality control, the available record suggests it was not caught during routine in-process checks and was discovered later in a reserve sample from one lot. That points to a defect that was either intermittent, limited to a small number of tablets, or not readily visible during standard release testing. Amgen’s recall notice also ties the issue to its AML Building 23 packaging area and references CGMP deviations, indicating the problem likely arose in or around packaging or handling rather than in the drug formulation itself. Because the exact contaminant has not been disclosed, it is not possible to say precisely why existing controls missed it. What is clear is that the company responded by recalling all in-date lots processed in the affected packaging area as a precaution, even though no related patient complaints had been reported. In practical terms, the bypass appears to have been a localized manufacturing or packaging quality lapse that only became evident during later sample review.

3 articles · Updated · Fox Business · Jun 27

944,142 bottles of Amgen's Corlanor and Sensipar tablets were voluntarily recalled nationwide after unexpected foreign matter was found in a reserve sample from one identified lot.
The material was found on the tablets' exterior coating, prompting Amgen to pull all unexpired lots processed in AML Building 23's packaging area as a precaution.
The FDA classified the action as a Class II recall, and California's Board of Pharmacy said hazard assessments found low overall patient risk with no complaints reported.
The affected heart-failure and kidney-disease drugs were distributed from Oct. 28, 2021, through Dec. 30, 2025, across six listed presentations.